Related references
Note: Only part of the references are listed.SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
Maja Nikolic et al.
HEART FAILURE REVIEWS (2022)
Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis
Alex Ali Sayour et al.
DIABETOLOGIA (2021)
SGLT2-inhibitors; more than just glycosuria and diuresis
Amir Fathi et al.
HEART FAILURE REVIEWS (2021)
Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice
Yihai Liu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure
Xuan Li et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia
Mohammed Ali Azam et al.
LIFE SCIENCES (2021)
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Kim A. Connelly et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Nikole J. Byrne et al.
CIRCULATION-HEART FAILURE (2020)
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
Marina Krasnova et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2020)
Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
Xiaodong Peng et al.
FRONTIERS IN PHYSIOLOGY (2020)
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Theodosios D. Filippatos et al.
POSTGRADUATE MEDICINE (2019)
Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
Binayak Sinha et al.
DIABETES THERAPY (2019)
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice
Mei Xue et al.
CLINICAL SCIENCE (2019)
Characterization of Myocardial Microstructure and Function in an Experimental Model of Isolated Subendocardial Damage
Niklas Beyhoff et al.
HYPERTENSION (2019)
Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
Chih-Chao Yang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts
Laween Uthman et al.
CARDIOVASCULAR RESEARCH (2019)
Regional diastolic dysfunction in post-infarction heart failure: role of local mechanical load and SERCA expression
Asmund T. Roe et al.
CARDIOVASCULAR RESEARCH (2019)
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
Anna Norhammar et al.
DIABETES OBESITY & METABOLISM (2019)
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats
Hiroto Oshima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
Kim A. Connelly et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
Ven G. Lim et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W. Mahaffey et al.
CIRCULATION (2018)
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes
Julian Mustroph et al.
ESC HEART FAILURE (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Ablation of Matrix Metalloproteinase-9 Prevents Cardiomyocytes Contractile Dysfunction in Diabetics
Priyanka Prathipati et al.
Frontiers in Physiology (2016)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen et al.
DIABETES CARE (2015)
Localizations of Na+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
Ivana Vrhovac et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2015)
Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor β1 in the Rat Heart
Dilyara Lauer et al.
HYPERTENSION (2014)
Novel aspects of excitation-contraction coupling in heart failure
Stefan Neef et al.
BASIC RESEARCH IN CARDIOLOGY (2013)
Na/Ca exchange and contraction of the heart
Michela Ottolia et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome
Svetlana Slavic et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2013)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Cleaved high molecular weight kininogen, a novel factor in the regulation of matrix metalloproteinases in vascular smooth muscle cells
Uwe Vosgerau et al.
BIOCHEMICAL PHARMACOLOGY (2010)
SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
Sanjay K. Banerjee et al.
CARDIOVASCULAR RESEARCH (2009)
Sodium hydrogen exchanger and phospholipase D are required for alpha(1)-adrenergic receptor stimulation of metalloproteinase-9 and cellular invasion in CCL39 fibroblasts
Jennifer Taves et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Angiotensin II Type 2 Receptor Stimulation A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?
Elena Kaschina et al.
CIRCULATION (2008)
The sodium bicarbonate cotransporter: Structure, function, and regulation
Angelito A. Bernardo et al.
SEMINARS IN NEPHROLOGY (2006)
Relative contributions of Na+/H+ exchange and Na+/HCO3- cotransport to ischemic Na-i(+) overload in isolated rat hearts
M Ten Hove et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Expression profile of genes regulated by activity of the Na-H exchanger NHE1
LK Putney et al.
BMC GENOMICS (2004)
Na+/H+ exchanger NHE1 as plasma membrane scaffold in the assembly of signaling complexes
M Baumgartner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
Share Paper
